Dan verteren we dat met wat lectuur ;-)
Ik koop vandaag wellicht 25 stuks bij.
Voor eind dit jaar minstens drie maal te herhalen.
Dagen als vandaag zijn zo globaal maar heeft niks te maken met ARWR.
We worden natuurlijk geheel meegesleurd door het putje.
Maar straks is er weer iets om de boel naar boven te krijgen.
Onderstaande tekst vind ik erg mooi samengevat.
Ik laat hem origineel. (Bron : Hoekiefun)
Pulled the primary completion dates of all the clinical trials moving forward. Take aways are we know Amg890 is moving into phase 3 is that news baked into the share price? We essentially are now running faster than Amg 890 in our Cardio drugs.
Enac is still a huge sleeper for price appreciation.
We know HSD is moving into phase 2b how does it synergize with market place, possibly jnj 1 and is it a break through therapy?
Jnj trials can extend for as much as 1 to 3 years longer from primary completion date. Let hope we have enough data to achieve an early treatment for patients. Remember we have also completed clinical trials in HBV.
Aro-Att is really the catalyst unless HBV gets a break through. It allows us to financially develop more internally.
Hif2a makes me wonder do we already have a partner for this one. Im still thinking we see an oncology partnership across multiple targets.
Can see why CA wants to continue to speed up Cta's and pipeline with the possible few years out still it might be best to continue to partner with other players in the space.
He has said they are keeping Cardio and C3 so what happens to Dux4, HSD, and others?
Amgen 890 Trial
12-Nov-22 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
3-Jan-22 Phase 2, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
23-Mar-22 An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(
22-Nov-22 An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(
7-Jun-23 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)
4-Oct-22 A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)
14-Apr-23 Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
3-Jul-23 A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)
Jul-23 Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
31-Oct-22 Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Jul-22 Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
30-Mar-22 Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
15-Dec-21 Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
13-Nov-21 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
13-Jul-22 Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT (SEQUOIA)
23-Aug-23 Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)